38 / 49
JO25567: PFS by independent review in all patients (primary endpoint)
75
72
69
64
60
53
49
38
30
20
13
8
4
4
0
77
66
57
44
39
29
24
21
18
12
10
5
2
1
0
T
A+T
Number at risk
0
0
1.0
Time (months)
4
8
12
2
6
10
14
18
22
26
16
20
24
28
0.2
0.4
0.6
0.8
PFS probability
9.7
16.0
Kato, et al. ASCO 2014
HR=0.54 (0.36–0.79)
Log-rank p<0.0015
Avastin + Tarceva
Tarceva